Klotho Neurosciences Files S-1 for $15M Preferred Stock Resale

TL;DR

**Klotho Neurosciences' S-1 is a red flag, signaling a massive insider share dump that will likely crush the stock price, so stay away.**

AI Summary

Klotho Neurosciences, Inc. (GRMLW) filed an S-1 on December 5, 2025, to register up to 35,000,000 shares of common stock for resale by existing selling stockholders. These shares include 34,883,722 shares issuable upon conversion of Series C Convertible Preferred Stock, which were sold in a private placement for an aggregate purchase price of $15,000,000, and 1,000,000 shares already held by a selling stockholder. The Series C Preferred Stock is convertible at an effective price of $0.44 per share. The company will not receive any proceeds from this resale offering, with all net proceeds going to the selling stockholders. Klotho Neurosciences' common stock trades on the NASDAQ Capital Market under the symbol "KLTO," and its average share price was $0.43 on December 2, 2025. The filing explicitly states that investing in their common shares involves a high degree of risk, and investors should be prepared for a complete loss.

Why It Matters

This S-1 filing signals a significant liquidity event for Klotho Neurosciences' early investors, allowing them to convert their Series C Preferred Stock and potentially sell up to 35,000,000 common shares. While the company itself won't receive direct proceeds, the influx of shares into the market could exert downward pressure on the stock price, impacting existing shareholders. For new investors, it highlights the high-risk nature of the investment, as explicitly stated in the filing, and the potential for dilution. In the competitive neuroscience sector, such a large resale could also be perceived as a lack of confidence by initial investors, potentially affecting market sentiment.

Risk Assessment

Risk Level: high — The S-1 filing explicitly states, "Investing in our common shares involves a high degree of risk. You should purchase shares only if you can afford a complete loss." Furthermore, the offering of up to 35,000,000 shares for resale by selling stockholders, representing a significant portion compared to the 72,536,722 shares outstanding prior to the offering, creates substantial potential for dilution and downward price pressure.

Analyst Insight

Investors should exercise extreme caution and consider avoiding Klotho Neurosciences (KLTO) stock. The large volume of shares being registered for resale by existing stockholders, from which the company receives no proceeds, suggests a potential lack of confidence from early investors and could lead to significant price volatility and declines.

Key Numbers

• 35,000,000 — Shares of Common Stock offered by Selling Stockholders (Represents the maximum number of shares that may be resold, including 34,883,722 from Series C conversion and 1,000,000 already held.)
• 72,536,722 — Shares of Common Stock Outstanding Prior to Offering (Provides context for the potential dilution from the resale offering.)
• $15,000,000 — Aggregate Purchase Price of Series C Preferred Stock (The amount raised by Klotho Neurosciences from the private placement, the shares from which are now being registered for resale.)
• $0.44 — Conversion Price per share for Series C Preferred Stock (The effective price at which Series C Preferred Stock converts into common stock.)
• $0.43 — Average Common Stock Price on Dec 2, 2025 (The market price used for registration fee calculation and a recent trading indicator.)
• 9.99% — Maximum Percentage Ownership for Conversion (A restriction on conversion of Series C Preferred Stock to prevent any single investor from owning too much common stock.)

Key Players & Entities

• Klotho Neurosciences, Inc. (company) — Registrant and issuer of common stock
• Joseph A. Sinkule (person) — Agent for service for Klotho Neurosciences, Inc.
• Paul Goodman, Esq. (person) — Attorney at Cyruli Shanks & Zizmor, LLP, counsel for Klotho Neurosciences, Inc.
• Cyruli Shanks & Zizmor, LLP (company) — Legal counsel for Klotho Neurosciences, Inc.
• SEC (regulator) — Securities and Exchange Commission
• NASDAQ Capital Market (company) — Stock exchange where Klotho Neurosciences' common stock is traded
• Continental Stock Transfer and Trust Company (company) — Transfer Agent for Klotho Neurosciences, Inc.
• $15,000,000 (dollar_amount) — Aggregate purchase price for Series C Convertible Preferred Stock in private placement
• $0.44 (dollar_amount) — Effective conversion price per share for Series C Convertible Preferred Stock
• $0.43 (dollar_amount) — Average of high and low sales prices of common shares on December 2, 2025

FAQ

Risk Factors

• High Risk Investment [high — financial]: Investing in Klotho Neurosciences' common shares involves a high degree of risk, and investors should be prepared for a complete loss of their investment. The company explicitly states this in the prospectus.
• Dilution from Resale Offering [high — financial]: The resale of up to 35,000,000 shares of common stock, issuable from Series C Preferred Stock conversion and existing holdings, could significantly dilute existing shareholders. This represents a substantial increase relative to the 72,536,722 shares outstanding prior to the offering.
• Dependence on Private Placement Conversion [medium — financial]: The offering is primarily based on the resale of shares from Series C Convertible Preferred Stock, which was sold for $15,000,000. The conversion price is $0.44 per share, and the market price on December 2, 2025, was $0.43, indicating potential for immediate selling pressure or a need for price appreciation.
• Stock Price Volatility [medium — market]: The company's common stock trades on the NASDAQ Capital Market under the symbol 'KLTO'. The average share price was $0.43 on December 2, 2025, and prices are subject to fluctuation based on market demand, posing a risk to investors.
• Registration Statement Effectiveness [low — regulatory]: The shares are being registered for resale, and the offering cannot commence until the registration statement becomes effective. Any delays or issues with SEC approval could impact the timing and execution of the resale.

Industry Context

Klotho Neurosciences operates in the biotechnology and pharmaceutical sector, focusing on neuroscience. This industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on private placements and public offerings to fund their operations and clinical trials.

Regulatory Implications

The S-1 filing is subject to SEC review and approval. The company must comply with securities laws regarding the registration and resale of shares. Any misstatements or omissions in the filing could lead to regulatory action and legal liabilities.

What Investors Should Do

1. Review 'Risk Factors' Thoroughly
2. Analyze Dilution Impact
3. Monitor Stock Performance Relative to Conversion Price
4. Understand the Company's Financial Health (if available in incorporated documents)

Key Dates

• 2025-12-05: S-1 Filing — Klotho Neurosciences filed its S-1 registration statement to allow existing stockholders to resell up to 35,000,000 shares of common stock.
• 2025-12-02: Common Stock Price Reference — The average share price of KLTO was $0.43, used for registration fee calculation and as a recent trading indicator.
• 2025-12-31: Expected Closing of Private Placement — The Series C Convertible Preferred Stock private placement is expected to close by this date, preceding the resale offering.

Glossary

S-1 Filing

A registration statement filed with the SEC by companies intending to offer securities to the public. It provides detailed information about the company's business, financial condition, and the securities being offered. (This filing allows existing stockholders to resell shares, and it contains crucial information for potential investors.)

Series C Convertible Preferred Stock

A class of preferred stock that can be converted into a predetermined number of common stock shares. It was sold in a private placement. (The conversion of these shares forms the basis for the majority of the shares being registered for resale.)

Resale Offering

An offering where existing shareholders sell their shares to the public, rather than the company issuing new shares. The company does not receive proceeds from a resale offering. (This entire S-1 filing is for a resale offering, meaning the company will not benefit financially from the sale of these shares.)

NASDAQ Capital Market

A stock exchange operated by Nasdaq, typically for smaller companies that meet certain financial and listing requirements. (Klotho Neurosciences' common stock (KLTO) is traded on this market, indicating its current public trading venue.)

Underwriters

Financial intermediaries that help companies issue securities to the public. In a resale offering, broker-dealers involved in the resale may be deemed underwriters. (This highlights potential roles and liabilities for parties facilitating the resale of shares.)

Year-Over-Year Comparison

This S-1 filing is for a resale of securities and does not appear to be a periodic report (like a 10-K or 10-Q) that would typically include year-over-year financial comparisons. Therefore, a direct comparison of revenue growth, margin changes, or new risks against a previous filing is not possible based on the provided text. The filing focuses on the mechanics of the resale and the risks associated with it.

Key Financial Figures

• $0.0001 — 3,722 shares of common stock, par value $0.0001 per share, of Klotho Neurosciences, Inc
• $0.43 — w sales prices of our common shares was $0.43 per share. These prices will fluctuate
• $15,000,000 — ase, for an aggregate purchase price of $15,000,000. a total of 3,400 shares of our Series
• $4,400 — Preferred Shares”) at a price of $4,400 per share subject to the terms and cond
• $0.44 — r Common Stock at an effective price of $0.44 per share (the “Conversion Price&
• $325,000 — c will receive an annual base salary of $325,000, and will receive an initial equity awa
• $360,000 — e will receive an annual base salary of $360,000, and will receive an equity award of 1,
• $120,000 — e amount involved exceeds the lesser of $120,000 or one percent of the average of our to

Filing Documents

• ea0268254-s1_klotho.htm (S-1) — 216KB
• ea026825401ex4-4_klotho.htm (EX-4.4) — 34KB
• ea026825401ex5-1_klotho.htm (EX-5.1) — 8KB
• ea026825401ex10-18_klotho.htm (EX-10.18) — 89KB
• ea026825401ex23-2_klotho.htm (EX-23.2) — 4KB
• ea026825401ex-fee_klotho.htm (EX-FILING FEES) — 14KB
• ex23-2_001.jpg (GRAPHIC) — 2KB
• 0001213900-25-118825.txt ( ) — 489KB
• ea026825401ex-fee_klotho_htm.xml (XML) — 5KB

forward-looking statements contained herein will prove to be accurate

forward-looking statements contained herein will prove to be accurate. 3 USE OF PROCEEDS On December 2, 2025 (the “Closing Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two investors (the “Investors”), pursuant to which the Investors will purchase, for an aggregate purchase price of $15,000,000. a total of 3,400 shares of our Series C Convertible Preferred Stock (the “Convertible Preferred Shares”) at a price of $4,400 per share subject to the terms and conditions set forth in the Purchase Agreement. The closing of the purchase of the Convertible Preferred Shares is excepted to occur on or about December 31, 2025. Pursuant to the Certificate of Designation of our Series C Convertible Preferred Stock, the original issuance price of the Convertible C Preferred Shares is convertible into shares of our Common Stock at an effective price of $0.44 per share (the “Conversion Price”); provided that no conversions can take place if an investor then owns more than 9.99% of the number of the shares of Common Stock outstanding (the “Maximum Percentage”). Further, no conversion can take place, prior to approval by the Company’s stockholders, if such conversion would violate any rule of the Nasdaq Stock Market. The Conversion Price is subject to adjustment in connection with certain transactions, including stock dividends, stock splits or combinations and the like. USE OF PROCEEDS We will not receive any proceeds from the sale of the Shares by the Selling Stockholders. All net proceeds from the sale of the Shares covered by this prospectus will go to the Selling Stockholders. We expect that the Selling Stockholders will sell their Shares as described under “Plan of Distribution.” The Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting,

View Full Filing

View this S-1 filing on SEC EDGAR